

+Please type a plus sign (+) inside this box → +

PTO/SB/08A/B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Att to #7

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number		
			Filing Date	August 21, 2001	
			First Named Inventor	KOVESDI, Imre	
			Group Art Unit	1632	
			Examiner Name		
Sheet	1	of	3	Attorney Docket Number	213187

J-828 U.S. PTO 09/934207

08/21/01

U.S. PATENT DOCUMENTS								
Examiner Initials ¹	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date If Appropriate
		Patent Number	Kind Code					
SDP	AA	6,133,028		Imler et al.	10-17-2000	435	325	
	AB	6,127,175		Vigne et al.	10-03-2000	435	325	
	AC	6,040,174		Imler et al.	03-21-2000	435	325	
	AD	5,518,913		Massie et al.	05-21-1996	435	235.1	
	AE	5,208,149		Inouye	05-04-1993	435	91.32 471	
	AF	5,190,931		Inouye	03-02-1993	435	91.32	
	AG	4,740,463		Weinberg et al.	04-26-1988	435	456	
	AH	4,727,028		Santerre et al.	02-23-1988	435	356	
	AI	4,497,796		Salser et al.	02-05-1985	514	44	
	AJ	4,405,712		Vande Woude	09-20-1983	435	5	

FOREIGN PATENT DOCUMENTS										
Examiner Initials ¹	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No*
SDP	AK	WO	96/22378	A	Rhone-Poulenc Rorer	07-25-1996	—	—		X ⁺
	AL	WO	95/27071	A	Univ. of Texas	10-12-1995	—	—		
	AM	WO	95/26411	A	UAB Res. Found.	10-05-1995	—	—		
	AN	CA	2,117,668	A	Sumitomo Pharm.	09-10-1995	—	—		
	AO	WO	95/16772	A	Cornell Res. Found.	06-22-1995	—	—		
	AP	AU	72646/94	A	Rhone-Poulenc Rorer	01-26-1995	—	—		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	Scott D. Priebe	Date Considered	11/6/02
--------------------	-----------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/934,207
				Filing Date	August 21, 2001
				First Named Inventor	KOVESDI, Imre
				Group Art Unit	1632
Examiner Name					
Sheet	2	of	3	Attorney Docket Number	213187

FOREIGN PATENT DOCUMENTS										
Examiner Initials ¹	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No*
SDP	AQ	FR	2707664	A	CNRS/Gustave Roussy	01-20-1995				
	AR	WO	95/00655	A	McMaster University	01-05-1995			Abstract only	X
	AS	WO	94/28938	A	University of Michigan	12-22-1994				
	AT	AU	68503/94	A	Transgene S.A.	12-08-1994				
	AU	WO	94/28152	A	Transgene S.A.	12-08-1994				
	AV	WO	94/26914	A	Rhone-Poulenc Rorer	11-24-1994			Abstract only	X
	AW	WO	94/24297	A	Rhone-Poulenc Rorer	10-27-1994			Abstract only	X
	AX	WO	94/12649	A	Genzyme Corp.	06-09-1994				
	AY	WO	94/11506	A	ARCH Devel. Corp.	05-26-1994				
	AZ	WO	94/08026	A	Rhone-Poulenc Rorer	04-14-1994				
	BA	CA	2,053,187	A	NRC Canada	04-11-1993				

OTHER - NON PATENT LITERATURE DOCUMENTS										
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.							Translation	
									Yes	No*
SDP	BB	BARR et al., <i>Gene Therapy</i> , 1 (1), 51-58 (January 1994).								
	BC	BERKNER et al., <i>Nucl. Acids Res.</i> , 11 (17), 6003-6020 (September 1983).								
	BD	BERKNER, <i>BioTechniques</i> , 6 (7), 616-629 (July/August 1988).								
	BE	BOUCHER et al., <i>Hum. Gene Ther.</i> , 5 (5), 615-639 (May 1994).								
	BF	BROUGH et al., <i>Virology</i> , 190 (2), 624-634 (October 1992).								
	BG	BROUGH et al., <i>Virology</i> , 196 (1), 269-281 (1993).								

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	Scott D. Pritch	Date Considered	11/6/02
--------------------	-----------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/934,207	
			Filing Date	August 21, 2001	
			First Named Inventor	KOVESDI, Imre	
			Group Art Unit	1632	
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	213187

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No*
SDP	BH	BRUNET et al., <i>Mol. Cell. Biol.</i> , 8 (11), 4799-4807 (November 1988).		
	BI	DAVIDSON et al., <i>J. Virol.</i> , 61 (4), 1226-1239 (April 1987).		
	BJ	ENGELHARDT et al., <i>PNAS USA</i> , 91 (13), 6196-6200 (June 1994).		
	BK	ENGLEHARDT et al., <i>Hum. Gene Ther.</i> , 4 (6), 759-769 (December 1993).		
	BL	GILARDI et al., <i>FEBS</i> , 267 (1), 60-62 (July 1990).		
	BM	GRAHAM et al., <i>J. Gen. Virol.</i> , 36 (1), 59-74 (July 1977).		
	BN	GRODZICKER et al., <i>Cell</i> , 21 (2), 453-463 (September 1980).		
	BO	KLESSIG et al., <i>Mol. Cell Biol.</i> , 4 (7), 1354-1362 (July 1984).		
	BP	LEMARCHAND et al., <i>PNAS USA</i> , 89 (14), 6482-6486 (July 1992).		
	BQ	MASTRANGELI et al., <i>J. Clin. Invest.</i> , 91 (1), 225-234 (January 1993).		
	BR	MITTEREDER et al., <i>Hum. Gene Ther.</i> , 5 (6), 771-729 (June 1994).		
	BS	MORIN et al., <i>Mol. Cell Biol.</i> , 9 (10), 4372-4380 (October 1989).		
	BT	ROBERTS et al., <i>J. Virol.</i> , 56 (2), 404-413 (November 1985).		
	BU	ROSENFELD et al., <i>Cell</i> , 68 (1), 143-158 (January 1992).		
	BV	SIMON et al., <i>Hum. Gene Ther.</i> , 4 (6), 771-780 (December 1993).		
	BW	VOS et al., <i>Virology</i> , 172 (2), 634-642 (October 1989).		
	BX	WEINBERG et al., <i>PNAS USA</i> , 80 (17), 5383-86 (September 1983).		
	BY	YANG et al., <i>PNAS USA</i> , 91 (10), 4407-4411 (May 1994).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	11/6/02
--------------------	--	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.